About | Drug Safety Conferences

Longdom Conferences provide the platform to speakers and offer delegates the opportunity to share their ideas and network. We are pleased to welcome you to attend and associate with us at 2^ndInternational Conference on Drug Safety and Pharmacovigilance on May 18-19, 2022 in Paris, France

Drug Safety 2022 mainly focuses on the theme “International Conference on Pharmaceutics and Drug Safety”. Guided by a line-up of expert speakers, researchers, doctors, students, professors and all the interested people in Pharmaceutics & Drug Safety from all over the world for our Drug Safety 2022 to ensure that public receives the best possible care and can look forward to a bright future.

Drug safety 2022, foresee over 200 participants from 7 continents with revolutionary subjects, discussions, and expositions. This will be excellent viability for the researchers, students and the delegates from Universities and Institutes to intermingle with the world-class scientists, speakers, technicians, technical practitioners and industry professionals working in the field of pharmaceutics and drug safety.

Scientific Sessions:

Pre-clinical and clinical trails
Adverse drug reactions
Good Pharmacovigilance practice
Drug Safety
Quality assurance
Prevalence of Potential Drugs
Pharmaceutical sciences

Track1 Pre-clinical and clinical trails

Clinical trials allow drug testing for safety assessment in different population. preclinical development referred as preclinical studies or nonclinical Studies, is a research stage carried at initial level of increasing accessibility and iterative testing and drug safety data are collected. Main goals of preclinical studies to determine the safe dose in first phase and evaluate the product safety profile. Product may include drugs, gene safety, and diagnostic tools.

Track 2- Adverse drug reactions

Adverse drug reaction is a form of toxicity or increase drug effect which mainly occurs during efficient use. In US 3-7% hospitalization are due to ADRs. ADRs occur during 10-20% of hospitalizations, 10-20% of ADRs are severe. ADR’s showed no pharmacokinetic effects resulting in 0% death incidence till date. suggested rate of 0.5 – 0.9% may be high because patient have some serious disorder. Severity and incidence vary through patients characteristic and through drug factors.

Track 3- Pharmacovigilance practice

Pharmacovigilance practice and pharmacoepidemiology in risk management to increase the possibility of beneficial effects of drug and adverse effects in population maintain reporting practice to avoiding the major problems in risk management. Also concentrate to examine information by collecting drug effects, caused by medicine. pharmacovigilance and clinical trial services should have pharmacovigilance certification.

Track1- Drug Safety

Statistics is playing an important role in clinical research in regulatory submission. Adverse drug reactions report can also be considered for the regulatory submission. pharmacovigilance process is achieved by ICH guidelines.

Track 5 Quality assurance

Quality assurance is a process by which we can prevent the mistakes and defects in manufactured product. So that, when we are delivering the product customers does not face any problem.

Track 6- Prevalence of Potential Drugs

The main purpose of this study is to evaluate the prevalence and explain the characteristics of PDDIs in medical recommendation of hospitalized surgical patients. In this transverse study, we examine 370 medical prescriptions from the surgery unit of a Mexican public teaching hospital. The classification and identification of potential drug-drug interactions were performed with the Micromedex 2.0 electronic drug information database. Results were examined with illustrative statistics and we estimated OR (odds ratio) to determine associated risk factors.

Track 7- Pharmaceutical sciences

The pharmaceutical science is an extortionate scope of logical controls of revelation and advancement of newly developed medications and treatments. Pharmaceutical sciences includes the basic fundamental standards of physical and compound science, designing, organic chemistry, and science to see how to upgrade transference of medications to the body and make an interpretation of this coordinated comprehension into as good as ever treatments against human ailment.

Market analysis

The international pharmaceutics and drug safety software market is assured to grow at a compound annual growth rate of 6.5% during 2014-2019, expected to achieve a value of $154.1 Million in 2019. As of 2014, North America bears the highest share of international Pharmacovigilance and drug safety software market, followed by Europe. Although, Asian and Latin American countries shows highest growth market, rise in research outsourcing by pharmaceutical giants and growing public and private investments in pharmaceutical R&D in these emerging nations

Updates
Solutions
Training
Surveillance
Services & Software’s
Reporting & Monitoring

International pharmaceuticals market was structured at $934.8 billion in 2017 and will reach $1170 billion in 2021, growing at 5.8%, according to the report of current Pharma market research by The Business Research Company. Speed up growth compared to 5.2% for the years before 2017 but slower than other two large healthcare segments, medical equipment, and healthcare services. Healthcare is growing at over 7% per year.

Past Conference Reports:

Euro Pharma 2020

We gratefully thank all our wonderful speakers and delegates for making the Euro Pharma 2020 webinar successful. International Webinaron Pharmaceutics and Drug Discovery, hosted by the Longdom Conference was held during June 15, 2020 at GMT+1 based on the theme “Innovations and Advancements in Pharmaceutics and Drug Discovery "